Rich Pharmaceuticals Inc. (fka RCHA)

[MaxYazger]

Rich Pharmaceuticals Inc. published a letter of intent with Khon Kaen University in Thailand to conduct clinical trials using Rich’s molecule therapy RP-323 in treating AML patients.

Presently, the university has four research centers of excellence and 23 research groups doing clinical research across numerous disease states with emphasis in conducting oncology clinical trials.

The commencement of the clinical studies is conditioned upon establishing a budget and timeline for the studies, and the execution of a definitive clinical study agreement with the Faculty of Medicine at Khon Kaen University. The clinical studies are estimated to include 36 patients at three separate sites.

http://www.cancerletter.com/articles/20150327_10